TapewireFind a company

person · Reporting owner

Norton David Y

Disclosed activity across 4 companies

Tapewire entity
43191
SEC CIK
0001529193

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
COMPASS Pathways plcCMPS · Entity 4567DirectorMay 27, 2026May 29, 2026
Syneos Health, Inc.INCR · Entity 109360DirectorMay 23, 2017May 24, 2017
VIVUS INCVVUS · Entity 151460DirectorFebruary 20, 2020February 24, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COMPASS Pathways plc

Report date May 27, 2026 · Filed May 29, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2036-05-26Direct21,110 Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-27 · Grant · Acquired 21,110 · Balance 21,110

F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Syneos Health, Inc.

Report date May 23, 2017 · Filed May 24, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect6,988 Reported balance After 2017-05-23 transaction · row 1
1 source row

Row 1 · 2017-05-23 · Grant · Acquired 2,693 · Balance 6,988

F1: Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors.

VIVUS INC

Report date February 20, 2020 · Filed February 24, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.41Direct15,000 Reported balance After 2020-02-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-02-20 · Grant · Acquired 15,000 · Balance 15,000

F1: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the monthly anniversary date following June 5, 2019, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates.

F2: The option expires on the earlier of (a) February 20, 2027 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider.

Filing footnotes · ownership attribution and instrument terms

F1: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the monthly anniversary date following June 5, 2019, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates.

F2: The option expires on the earlier of (a) February 20, 2027 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Keenova Therapeutics plc

Report date June 16, 2022 · Filed June 21, 2022

Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 27, 2026 Filed May 29, 2026 21:11 UTC COMPASS Pathways plc CMPS · Entity 4567 GrantShare Option (Right to Buy) · Derivative 21,110 $0.00 Strike: $11.85 $0.00
Disclosure

SEC source: 0001529193-26-000002 · wk-form4_1780089107.xml · derivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,110

Underlying: Ordinary Shares · 21,110 shares

Expires 2036-05-26

F1 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 12, 2025 Filed Jun 13, 2025 12:26 UTC COMPASS Pathways plc CMPS · Entity 4567 GrantShare Option (Right to Buy) · Derivative 26,000 $0.00 Strike: $4.52 $0.00
Disclosure

SEC source: 0001816590-25-000079 · wk-form4_1749817570.xml · derivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Ordinary Shares · 26,000 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
May 09, 2024 Filed May 13, 2024 10:43 UTC COMPASS Pathways plc CMPS · Entity 4567 GrantShare Option (Right to Buy) · Derivative 39,000 $0.00 Strike: $8.54 $0.00
Disclosure

SEC source: 0001816590-24-000094 · wk-form4_1715596993.xml · derivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,000

Underlying: Ordinary Shares · 39,000 shares

Expires 2034-05-08

F1 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2025.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
June 02, 2023 Filed Jun 6, 2023 20:22 UTC COMPASS Pathways plc CMPS · Entity 4567 GrantShare Option (Right to Buy) · Derivative 26,000 $0.00 Strike: $7.88 $0.00
Disclosure

SEC source: 0001816590-23-000084 · wk-form4_1686082939.xml · derivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Ordinary Shares · 26,000 shares

Expires 2033-06-01

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual Meeting of Shareholders in 2024.

Read SEC document
June 16, 2022 Filed Jun 17, 2022 20:09 UTC COMPASS Pathways plc CMPS · Entity 4567 GrantShare Option (Right to Buy) · Derivative 17,000 $0.00 Strike: $9.41 $0.00
Disclosure

SEC source: 0001816590-22-000057 · wf-form4_165549656731377.xml · derivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Ordinary Shares · 17,000 shares

Expires 2032-06-15

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual Meeting of Shareholders in 2023.

Read SEC document
March 29, 2022 Filed Mar 31, 2022 18:12 UTC COMPASS Pathways plc CMPS · Entity 4567 SaleOrdinary Shares 3,384 $12.48 $42,232.32
Disclosure

SEC source: 0001816590-22-000018 · wf-form4_164875032876665.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,356

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · shares: Shares were sold to satisfy payment of a tax liability upon Restricted Share Units ("RSUs") vesting.

F3 · balance_after: Includes 23,740 RSUs granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. 25% of the RSUs vested on August 12, 2021, with the remainder vesting in twelve equal quarterly installments thereafter.

Read SEC document
August 05, 2021 Filed Aug 9, 2021 13:09 UTC Keenova Therapeutics plc MNKKQ · Entity 28960 SaleOrdinary Shares 5,080 $0.26 $1,334.01
Disclosure

SEC source: 0001235110-21-000021 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.2506 to $0.2628, inclusive. Mr. Norton will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.

Read SEC document
December 17, 2020 Filed Dec 18, 2020 21:20 UTC Keenova Therapeutics plc MNKKQ · Entity 28960 SaleOrdinary Shares 5,080 $0.40 $2,054.35
Disclosure

SEC source: 0000950138-20-000537 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.401 to $0.408, inclusive. Mr. Norton will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.

Read SEC document
December 16, 2020 Filed Dec 18, 2020 12:33 UTC Keenova Therapeutics plc MNKKQ · Entity 28960 SaleOrdinary Shares 21,807 $0.43 $9,462.06
Disclosure

SEC source: 0000950138-20-000531 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,080

F1 · price: The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.432 to $0.44, inclusive. Mr. Norton will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.

Read SEC document
May 13, 2020 Filed May 15, 2020 20:26 UTC Keenova Therapeutics plc MNK · Entity 28960 Tax withholdingOrdinary Shares 8,729 $2.96 $25,837.84
Disclosure

SEC source: 0000950138-20-000259 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,167

Read SEC document
February 20, 2020 Filed Feb 24, 2020 18:06 UTC VIVUS INC VVUS · Entity 151460 GrantNon-Qualified Stock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $2.41 $0.00
Disclosure

SEC source: 0001123292-20-000325 · edgar.xml · derivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F1 · derivative.exercise_date: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the monthly anniversary date following June 5, 2019, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates.

F2 · derivative.expiration_date: The option expires on the earlier of (a) February 20, 2027 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider.

Read SEC document
May 15, 2019 Filed May 17, 2019 10:57 UTC Keenova Therapeutics plc MNK · Entity 28960 GrantOrdinary Shares 19,396 $0.00 $0.00
Disclosure

SEC source: 0000950138-19-000310 · edgar.xml · nonDerivative · entry 2

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,896

F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2020 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting.

Read SEC document
May 15, 2019 Filed May 17, 2019 10:57 UTC Keenova Therapeutics plc MNK · Entity 28960 Tax withholdingOrdinary Shares 8,527 $15.21 $129,695.67
Disclosure

SEC source: 0000950138-19-000310 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,500

Read SEC document
October 26, 2018 Filed Oct 29, 2018 19:47 UTC VIVUS INC VVUS · Entity 151460 GrantNon-Qualified Stock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $3.53 $0.00
Disclosure

SEC source: 0001123292-18-001041 · edgar.xml · derivative · entry 2

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F2 · derivative.exercise_date: One twelfth (1/12th) of the total number of shares underlying the option vest and become exercisable on the 26th of each month following October 26, 2018, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2018 Equity Incentive Plan) on the relevant vesting dates.

F3 · derivative.expiration_date: The option expires on the earlier of (a) October 26, 2025 and (b) the six (6) month anniversary of the date the reporting person ceases to be a Service Provider.

Read SEC document
May 16, 2018 Filed May 18, 2018 20:36 UTC Keenova Therapeutics plc MNK · Entity 28960 GrantOrdinary Shares 18,947 $0.00 $0.00
Disclosure

SEC source: 0000950138-18-000423 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,027

F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2019 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting.

Read SEC document
March 01, 2018 Filed Mar 5, 2018 21:32 UTC Keenova Therapeutics plc MNK · Entity 28960 Tax withholdingOrdinary Shares 2,521 $15.68 $39,529.28
Disclosure

SEC source: 0000950138-18-000214 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,080

Read SEC document
November 10, 2017 Filed Nov 13, 2017 21:12 UTC Keenova Therapeutics plc MNK · Entity 28960 PurchaseOrdinary Shares 2,000 $22.02 $44,030.00
Disclosure

SEC source: 0000950138-17-000750 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,601

Read SEC document
October 27, 2017 Filed Oct 31, 2017 17:43 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionRestricted Stock Units · Derivative 12,500 $0.00 $0.00
Disclosure

SEC source: 0001123292-17-001646 · edgar.xml · derivative · entry 4

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

F4 · derivative.exercise_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month.

F4 · derivative.expiration_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month.

Read SEC document
October 27, 2017 Filed Oct 31, 2017 17:43 UTC VIVUS INC VVUS · Entity 151460 GrantNon-Qualified Stock Option (right to buy) · Derivative 150,000 $0.00 Strike: $0.70 $0.00
Disclosure

SEC source: 0001123292-17-001646 · edgar.xml · derivative · entry 3

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2024-10-27

F1 · derivative.exercise_date: One twelfth (1/12th) of the total number of shares subject to the option shall vest and become exercisable on the 27th of each month following October 27, 2017, subject to such individual continuing to be a Service Provider (as defined in the 2010 Equity Incentive Plan) on the relevant vesting dates.

Read SEC document
October 27, 2017 Filed Oct 31, 2017 17:43 UTC VIVUS INC VVUS · Entity 151460 Disposition to issuerCommon Stock 3,125 $0.70 $2,187.50
Disclosure

SEC source: 0001123292-17-001646 · edgar.xml · nonDerivative · entry 2

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,120

F3 · kind: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability.

Read SEC document
October 27, 2017 Filed Oct 31, 2017 17:43 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionCommon Stock 12,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001123292-17-001646 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,245

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

Read SEC document
September 20, 2017 Filed Sep 22, 2017 12:36 UTC Keenova Therapeutics plc MNK · Entity 28960 GrantOrdinary Shares 5,601 $0.00 $0.00
Disclosure

SEC source: 0000950138-17-000648 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,601

F1 · shares: Consists of restricted stock units that vest in their entirety as of March 1, 2018. The restricted stock units settle in ordinary shares upon vesting.

Read SEC document
August 08, 2017 Filed Aug 10, 2017 16:16 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionRestricted Stock Units · Derivative 12,500 $0.00 $0.00
Disclosure

SEC source: 0001123292-17-001337 · edgar.xml · derivative · entry 3

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

F3 · derivative.exercise_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month.

F3 · derivative.expiration_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month.

Read SEC document
August 08, 2017 Filed Aug 10, 2017 16:16 UTC VIVUS INC VVUS · Entity 151460 Disposition to issuerCommon Stock 3,125 $1.01 $3,156.25
Disclosure

SEC source: 0001123292-17-001337 · edgar.xml · nonDerivative · entry 2

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,745

F2 · kind: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability.

Read SEC document
August 08, 2017 Filed Aug 10, 2017 16:16 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionCommon Stock 12,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001123292-17-001337 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,870

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

Read SEC document
June 15, 2017 Filed Jun 19, 2017 18:52 UTC VIVUS INC VVUS · Entity 151460 Disposition to issuerCommon Stock 3,125 $1.17 $3,656.25
Disclosure

SEC source: 0001123292-17-001144 · edgar.xml · nonDerivative · entry 2

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,370

F2 · kind: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability.

Read SEC document
May 23, 2017 Filed May 24, 2017 20:15 UTC Syneos Health, Inc. INCR · Entity 109360 GrantClass A Common Stock 2,693 $0.00 $0.00
Disclosure

SEC source: 0001529193-17-000001 · wf-form4_149565689941524.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,988

F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors.

Read SEC document
May 08, 2017 Filed Jun 19, 2017 18:52 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionRestricted Stock Units · Derivative 12,500 $0.00 $0.00
Disclosure

SEC source: 0001123292-17-001144 · edgar.xml · derivative · entry 3

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

F3 · derivative.exercise_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month.

F3 · derivative.expiration_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month.

Read SEC document
May 08, 2017 Filed Jun 19, 2017 18:52 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionCommon Stock 12,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001123292-17-001144 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,495

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

Read SEC document
February 08, 2017 Filed Feb 10, 2017 16:02 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionRestricted Stock Units · Derivative 12,500 $0.00 $0.00
Disclosure

SEC source: 0001123292-17-000336 · edgar.xml · derivative · entry 3

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

F3 · derivative.exercise_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month.

F3 · derivative.expiration_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month.

Read SEC document
February 08, 2017 Filed Feb 10, 2017 16:02 UTC VIVUS INC VVUS · Entity 151460 Disposition to issuerCommon Stock 3,125 $1.08 $3,375.00
Disclosure

SEC source: 0001123292-17-000336 · edgar.xml · nonDerivative · entry 2

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,995

F2 · kind: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability.

Read SEC document
February 08, 2017 Filed Feb 10, 2017 16:02 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionCommon Stock 12,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001123292-17-000336 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,120

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

Read SEC document
January 13, 2017 Filed Jan 18, 2017 16:09 UTC VIVUS INC VVUS · Entity 151460 GrantRestricted Stock Units · Derivative 50,000 $0.00 $0.00
Disclosure

SEC source: 0001123292-17-000182 · edgar.xml · derivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VIVUS, Inc. common stock.

F2 · derivative.exercise_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month.

F2 · derivative.expiration_date: The restricted stock units (RSUs) vest according to the following schedule: Commencing on November 8, 2016, 1/4th of the total RSUs originally granted shall vest on each of February 8, 2017, May 8, 2017, August 8, 2017 and November 8, 2017; provided, however, that (a) if the next annual stockholder meeting occurs prior to November 8, 2017 and the individual has remained a Service Provider (as defined in the VIVUS, Inc. 2010 Equity Incentive Plan), the vesting of the RSUs shall accelerate in full as of the date of the next annual stockholder meeting and (b) if the individual ceases to be a Service Provider (other than removal for cause) prior to any of the foregoing vesting dates, then 1/12th of the shares underlying the RSUs shall accelerate for each month elapsed from the most recent vesting date until the month in which the individual (i) ceases to be a Service Provider and (ii) has remained a Service Provider through at least the 8th day of such month.

Read SEC document
October 31, 2016 Filed Nov 1, 2016 16:29 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionRestricted Stock Units · Derivative 3,125 $0.00 $0.00
Disclosure

SEC source: 0001123292-16-002918 · edgar.xml · derivative · entry 3

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

F3 · derivative.exercise_date: The restricted stock units vest according to the following schedule: 7/12ths of the total restricted stock units originally granted vested on May 30, 2016, and an additional 1/12th of the total restricted stock units originally granted vest on the last day of each calendar month thereafter, subject to the individual continuing to be a Service Provider (as defined in the 2010 Equity Incentive Plan) on the relevant vesting dates.

F3 · derivative.expiration_date: The restricted stock units vest according to the following schedule: 7/12ths of the total restricted stock units originally granted vested on May 30, 2016, and an additional 1/12th of the total restricted stock units originally granted vest on the last day of each calendar month thereafter, subject to the individual continuing to be a Service Provider (as defined in the 2010 Equity Incentive Plan) on the relevant vesting dates.

Read SEC document
October 31, 2016 Filed Nov 1, 2016 16:29 UTC VIVUS INC VVUS · Entity 151460 Disposition to issuerCommon Stock 781 $1.05 $820.05
Disclosure

SEC source: 0001123292-16-002918 · edgar.xml · nonDerivative · entry 2

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,620

F2 · kind: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability.

Read SEC document
October 31, 2016 Filed Nov 1, 2016 16:29 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionCommon Stock 3,125 Not disclosed Not disclosed
Disclosure

SEC source: 0001123292-16-002918 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,401

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

Read SEC document
September 30, 2016 Filed Oct 4, 2016 19:27 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionRestricted Stock Units · Derivative 3,125 $0.00 $0.00
Disclosure

SEC source: 0001123292-16-002799 · edgar.xml · derivative · entry 3

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,125

Underlying: Common Stock · 3,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

F3 · derivative.exercise_date: The restricted stock units vest according to the following schedule: 7/12ths of the total restricted stock units originally granted vested on May 30, 2016, and an additional 1/12th of the total restricted stock units originally granted vest on the last day of each calendar month thereafter, subject to the individual continuing to be a Service Provider (as defined in the 2010 Equity Incentive Plan) on the relevant vesting dates.

F3 · derivative.expiration_date: The restricted stock units vest according to the following schedule: 7/12ths of the total restricted stock units originally granted vested on May 30, 2016, and an additional 1/12th of the total restricted stock units originally granted vest on the last day of each calendar month thereafter, subject to the individual continuing to be a Service Provider (as defined in the 2010 Equity Incentive Plan) on the relevant vesting dates.

Read SEC document
September 30, 2016 Filed Oct 4, 2016 19:27 UTC VIVUS INC VVUS · Entity 151460 Disposition to issuerCommon Stock 781 $1.14 $890.34
Disclosure

SEC source: 0001123292-16-002799 · edgar.xml · nonDerivative · entry 2

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,276

F2 · kind: The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability.

Read SEC document
September 30, 2016 Filed Oct 4, 2016 19:27 UTC VIVUS INC VVUS · Entity 151460 Exercise / conversionCommon Stock 3,125 Not disclosed Not disclosed
Disclosure

SEC source: 0001123292-16-002799 · edgar.xml · nonDerivative · entry 1

Norton David Y · CIK 0001529193 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,057

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.